

The long-term impact of immunotherapy and targeted therapy on outcomes in patients with brain metastases

Published: 01-05-2023

Last updated: 27-12-2024

To determine outcomes in long-term surviving brain metastases patients (≥ 2 years after diagnosis of brain metastases) treated with immunotherapy or targeted therapy.

| | |
|------------------------------|----------------------------|
| Ethical review | Approved WMO |
| Status | Recruiting |
| Health condition type | Metastases |
| Study type | Observational non invasive |

Summary

ID

NL-OMON53728

Source

ToetsingOnline

Brief title

LFUBM

Condition

- Metastases
- Nervous system neoplasms malignant and unspecified NEC

Synonym

Brain metastases; Cancer that has spread to the brain

Research involving

Human

Sponsors and support

Primary sponsor: Leids Universitair Medisch Centrum

Source(s) of monetary or material Support: het onderzoek wordt uitgevoerd door onderzoekers die reeds op andere subsidies zitten;en/of studenten Geneeskunde

Intervention

Keyword: Brain metastases, Health-related quality of life, Long term outcomes, Neurocognition

Outcome measures

Primary outcome

- Neurocognitive functioning
- Instrumental activities of daily living
- Health-related quality of life
- Epilepsy
- Radiological abnormalities (cerebral abnormalities and treatment-induced radiological abnormalities)

Secondary outcome

Sociodemographic information (i.e. age at study assessments, gender, level of education, marital status and living arrangements, current or last profession) and clinical information (Karnofsky Performance Status, date of diagnosis primary cancer, relevant histological and molecular tumor information, sites of metastases, date of diagnosis brain metastases, number and location of brain metastases, previously received anti-tumor treatment and anti-tumor treatment at assessment, corticosteroid and antiepileptic drug use, and comorbidity).

Study description

Background summary

While prolonged survival can be achieved for patients with brain metastases from any stage IV solid primary cancer treated with newer treatments such as immunotherapy and targeted therapy, information on the impact of these

treatments on different outcomes, including those relevant to patients such as the level of functioning and well-being, is scarce.

Study objective

To determine outcomes in long-term surviving brain metastases patients (≥ 2 years after diagnosis of brain metastases) treated with immunotherapy or targeted therapy.

Study design

This will be a multicenter cross-sectional study on the long-term outcomes of brain metastases patients treated with immunotherapy or targeted therapy.

Study burden and risks

While prolonged survival can be achieved for patients with brain metastases treated with newer treatments such as immunotherapy and targeted therapy, information on the impact of these treatment on different outcomes, including those relevant to patients such as the level of functioning and well-being, is scarce. This study will provide information about the net clinical benefit of certain treatment strategies for patients with brain metastases, which can be used in clinical decision-making. Although the included patients will not benefit from this knowledge themselves, the results are valuable for future patients. The risk and burden of this study for the participating patients is minimal, although filling in the questionnaires and undergoing the neurocognitive tests may be perceived as tiresome for some patients.

Contacts

Public

Leids Universitair Medisch Centrum

Albinusdreef 2
Leiden 2333 ZA
NL

Scientific

Leids Universitair Medisch Centrum

Albinusdreef 2
Leiden 2333 ZA
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years)

Elderly (65 years and older)

Inclusion criteria

- Any histologically confirmed stage IV solid primary cancer and radiologically confirmed brain metastases;
- Adult patients: ≥ 18 years of age;
- Treated with immunotherapy and/or targeted therapy (as monotherapy, combined or in combination with other treatment modalities);
- Diagnosis of brain metastases ≥ 2 years ago;
- Willing to provide written informed consent.

Exclusion criteria

- Patients without understanding of the Dutch language, hampering the completion of questionnaires or undergoing neurocognitive testing;
- Patients with a poor physical condition or any psychiatric condition or cognitive impairment, as determined by the treating physician, that will hamper them to provide consent to research or undergo neurocognitive testing or completion of the questionnaires.

Study design

Design

Study type: Observational non invasive

Masking: Open (masking not used)

| | |
|------------------|--------------|
| Control: | Uncontrolled |
| Primary purpose: | Other |

Recruitment

| | |
|---------------------------|------------|
| NL | |
| Recruitment status: | Recruiting |
| Start date (anticipated): | 05-10-2023 |
| Enrollment: | 72 |
| Type: | Actual |

Ethics review

| | |
|--------------------|-------------------------------------|
| Approved WMO | |
| Date: | 01-05-2023 |
| Application type: | First submission |
| Review commission: | METC Leiden-Den Haag-Delft (Leiden) |
| | metc-ldd@lumc.nl |

| | |
|--------------------|-------------------------------------|
| Approved WMO | |
| Date: | 11-12-2024 |
| Application type: | Amendment |
| Review commission: | METC Leiden-Den Haag-Delft (Leiden) |
| | metc-ldd@lumc.nl |

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

| Register | ID |
|----------|----------------|
| CCMO | NL81888.058.22 |